Carbidopa/levodopa/entacapone

Neurocrine Biosciences Announces Once-Daily ONGENTYS® (opicapone) Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes

Retrieved on: 
Monday, September 14, 2020
Drugs, Catecholamines, RTT, Combination drugs, Carbidopa, Hydrazines, Prodrugs, Parkinson's disease, L-DOPA, Carbidopa/levodopa/entacapone, Catechol-O-methyltransferase inhibitor

ONGENTYS was approved by the U.S. Food and Drug Administration (FDA) on April 24, 2020, as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.

Key Points: 
  • ONGENTYS was approved by the U.S. Food and Drug Administration (FDA) on April 24, 2020, as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing "off" episodes.
  • ONGENTYS helps protect levodopa by reducing its breakdown in the bloodstream, making more levodopa available to reach the brain.
  • "The availability of ONGENTYS offers hope to patients by significantly reducing daily 'off' time, when symptoms return between regular doses of levodopa/carbidopa.
  • The availability of ONGENTYS underscores our commitment to delivering innovative therapies that address unmet medical needs in patients living with movement disorders."

Neurocrine Biosciences Presents New Data Analyses Demonstrating Efficacy of FDA-Approved Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the MDS Virtual Congress 2020

Retrieved on: 
Friday, September 11, 2020
Drugs, Health, Catecholamines, RTT, Combination drugs, Amino acids, Carbidopa, Hydrazines, Parkinson's disease, L-DOPA, Carbidopa/levodopa/entacapone, Management of Parkinson's disease

These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).

Key Points: 
  • These data are among several studies and analyses of ONGENTYS being presented in collaboration with BIAL at the MDS Virtual Congress 2020 on September 1216 ( www.mdscongress.org/Congress/Registration.htm ).
  • "The Phase III post-hoc data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa in patients with Parkinson's disease who have motor fluctuations.
  • "These data analyses demonstrated the benefit of adding once-daily ONGENTYS to levodopa/carbidopa earlier in the treatment regimen of patients with Parkinson's disease.
  • Similarly, hospitalizations were significantly more frequent in patients with a longer history of motor fluctuations (15% [n=18] vs 6% [n=12], P

Assessment of the Levodopa-Induced Dyskinesia (LID) Pipeline, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Health, Pharmaceutical, Parkinson's disease, Organ systems, Nervous system, Drugs, Levodopa-induced dyskinesia, Dyskinesia, L-DOPA, Dipraglurant, Carbidopa/levodopa/entacapone

The "Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Levodopa-Induced Dyskinesia (LID) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Levodopa-Induced Dyskinesia (LID) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Levodopa-Induced Dyskinesia (LID) market.
  • A detailed picture of the Levodopa-Induced Dyskinesia (LID) pipeline landscape is provided, which includes the disease overview and Levodopa-Induced Dyskinesia (LID) treatment guidelines.
  • The assessment part of the report embraces in-depth Levodopa-Induced Dyskinesia (LID) commercial assessment and clinical assessment of the Levodopa-Induced Dyskinesia (LID) pipeline products from the pre-clinical developmental phase to the marketed phase.

Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes

Retrieved on: 
Thursday, June 4, 2020
Psychoactive drugs, Parkinson's disease, Neurological disorders, Organ systems, Amantadine, Dyskinesia, L-DOPA, Levodopa-induced dyskinesia, Carbidopa/levodopa/entacapone

GOCOVRI (amantadine) extended release capsules is approved to treat dyskinesia in PD patients treated with levodopa-based therapy, with or without other dopaminergic medications.

Key Points: 
  • GOCOVRI (amantadine) extended release capsules is approved to treat dyskinesia in PD patients treated with levodopa-based therapy, with or without other dopaminergic medications.
  • In the sNDA, Adamas has proposed a revision to the indication statement to include GOCOVRI as an appropriate therapy for the treatment of OFF episodes in PD patients receiving levodopa.
  • The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia.
  • Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

The Global Market for Parkinson's Disease Drugs to 2024 - COMT (Catechol-O-Methyltransferase) Inhibitors to Register Robust Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 10, 2019
Health, Pharmaceutical, Aromatic compounds, Organic compounds, Catechols, Catechol-O-methyltransferase inhibitor, Nitrophenols, Catechol-O-methyltransferase, Tolcapone, Entacapone, Parkinson's disease, Pharmacological treatment of Parkinson's disease, Carbidopa/levodopa/entacapone

The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
  • Parkinson's disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson's disease, with the growth in aging population levels.
  • The two most common COMT inhibitors, used in the treatment of Parkinson's disease, are Comtan (entacapone) and Tasmar (tolcapone).
  • The sheer number of Parkinson's disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market.

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations

Retrieved on: 
Sunday, May 5, 2019
Parkinson's disease, Neurological disorders, Chemical compounds, Organ systems, Opicapone, Management of Parkinson's disease, Dyskinesia, L-DOPA, Catechol-O-methyltransferase inhibitor, Carbidopa/levodopa/entacapone

The analysis found that treatment with opicapone 50 mg, added to levodopa, resulted in a significant and sustained increase in ON time without troublesome dyskinesia1, in Parkinson's disease patients with motor fluctuations.

Key Points: 
  • The analysis found that treatment with opicapone 50 mg, added to levodopa, resulted in a significant and sustained increase in ON time without troublesome dyskinesia1, in Parkinson's disease patients with motor fluctuations.
  • "Webelieve this data will translate intoreal-world benefits for Parkinson's disease patients on levodopa therapy who experience motor fluctuations, which can be disruptive and impact the patient's quality of life."
  • Opicapone is in development in the U.S. for adjunctive use with levodopa for the treatment of Parkinson's disease.
  • "Based on the Phase III data analysis, we believe once-daily opicapone has the potential to prolong the clinical effects of levodopa and help patients achieve symptom control so they can better cope with this debilitating disease."

Amneal Announces Issuance of New Patent for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa

Retrieved on: 
Wednesday, October 24, 2018
Catecholamines, Chemistry, Medicine, Clinical medicine, RTT, Carbidopa, Hydrazines, L-DOPA, Parkinson's disease, Patent, United States Patent and Trademark Office, Carbidopa/levodopa/entacapone

BRIDGEWATER, N.J., Oct. 24, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that a patent protectingIPX203has been issued by the United States Patent and Trademark Office.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 24, 2018 /PRNewswire/ --Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that a patent protectingIPX203has been issued by the United States Patent and Trademark Office.
  • "The issuance of this patent supports our intellectual property strategy for IPX203," said Rob Stewart, President and CEO of Amneal.
  • "We have initiated a Phase 3 Study and expect to enroll our first patient shortly.
  • IPX203 is an investigational extended-release oral capsule formulation of carbidopa and levodopa (CD-LD), being studied as a potential treatment for the symptoms of advanced Parkinson's disease.